Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$23.22 – $37.15
68% from low
Exchange
NASDAQ
ETF
Borrow rate
13.34%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| OZEMRoundhill Investments - GLP-1 & Weight Loss ETF | $32.70 | -0.12% | $42M | — |
| CEFZRiverNorth Active Income ETF | $8.23 | +0.63% | $40M | — |
| FLAXFranklin FTSE Asia ex Japan ETF | $37.32 | +1.65% | $54M | — |
| HOMZHoya Capital Housing ETF | $47.77 | -0.23% | $34M | — |
| KEMQKraneShares FTSE Emerging Markets Consumer Technology Index ETF |
No company description on file.
No one on the platform currently holds OZEM.
No tracked institution reports a position in OZEM as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-30 | $0.4099 | 2025-12-31 |
| 2024-12-30 | $0.0531 | 2024-12-31 |
No one on the platform has traded OZEM yet.
| $25.66 |
| +0.51% |
| $34M |
| — |
| NBJPNeuberger Berman Japan Equity ETF | $37.05 | +0.27% | $45M | — |
| NIXTResearch Affiliates Deletions ETF | $32.36 | -0.32% | $38M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst $HIMS $OZEM https://stocktwits.com/news/equity/markets/hims-stock-breakout-peptides-glp1-growth/cZK0wLiR7IV
View on StockTwits ↗HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout? $HIMS $EDOC $OZEM https://stocktwits.com/news/equity/markets/hims-stock-gains-eyes-on-breakout/cZKfp1LR73n
View on StockTwits ↗4️⃣ $OZEM - Roundhill GLP-1 & Weight Loss ETF Sporting a 19.08% allocation to $LLY. The first pure-play ETF targeting the anti-obesity global theme. Given its specialized exposure to pure anti-obesity competitors, localized sector profit-taking weighed on performance over the trailing 5 sessions: 📉 5D Return: -4.09% 📊 Expense Ratio: 0.59%
View on StockTwits ↗LLY Stock Heads To Record High – Here’s Why Retail’s Bullish On Latest GLP-1 Data $LLY $OZEM https://stocktwits.com/news/equity/markets/lly-stock-heads-to-record-high-heres-why/cZ0vRnLR7G2
View on StockTwits ↗TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant $LLY $OZEM $NVO $HIMS https://stocktwits.com/news/equity/markets/td-cowen-glp1-sales-forecast-lilly-novo-to-remain-leaders/cZ0FkzQReCB
View on StockTwits ↗$SPY $QQQ $NVO $OZEM If you're on a GLP1 with the only purpose to lose a small amount of body fat....
View on StockTwits ↗$OZEM Current Stock Price: $31.40 Contracts to trade: $26.0 OZEM May 15 2026 Call Entry: $5.10 Exit: $9.38 ROI: 84% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$RKTO easy buy to north!!! Obesity is one of the worlds issues… buy up bulls to 1$ 🔥‼️ $SLNH $OZEM $IBRX $UAVS
View on StockTwits ↗Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80% $GLENMARK.NSE $OZEM $LLY $NVO https://stocktwits.com/news/equity/markets/glenmark-debuts-budget-semaglutide-in-india/cZ3i3maRIih
View on StockTwits ↗Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial $LLY $OZEM https://stocktwits.com/news/equity/markets/eli-lilly-oral-glp1-orforglipron-beats-semaglutide-phase-3-trials/cZTG90fRIbo
View on StockTwits ↗Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes $NVO $LLY $OZEM $THNR $PPH https://stocktwits.com/news/equity/markets/novo-vivtex-deal-to-develop-oral-medicines-for-obesity-diabetes/cZRydmtRIGP
View on StockTwits ↗Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report $NVO $OZEM $PPH https://stocktwits.com/news/equity/markets/novo-looks-to-ireland-to-scale-production-of-wegovy-pill-report/cZRT0F6R4rc
View on StockTwits ↗Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial $RKTO $HIMS $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/hoth-therapeutics-gdnf-treatment-shows-superior-efficacy-over-wegovy-ozempic-in-preclinical-trial/cZbUJr3R4p2
View on StockTwits ↗$HIMS $OZEM ....with around 35% of the float short and a P/E of 42.5.....How does this not drop to $9.00 on Monday?....If the lawyers do not eat up all their 'profits' quickly, then shareholders, unhappy with how mgmt headline grabbing news yesterday has "exposed" the company now to countless retail lawsuits, on the premise that the FDA had warned them prior about compounding a FDA regulated drug product w/o their stamp of approval...seems mgmt was not listening nor paying attention to the regulators when they had a fiduciary duty to "protect" shareholders...oh well...nobody likes to see other investors lose but mgmt at HIMS seems to have brought the hammer down on their and their shareholders head. glta
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.